1. Academic Validation
  2. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model

Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model

  • J Med Chem. 2009 Dec 10;52(23):7364-7. doi: 10.1021/jm900518f.
Eddy W Yue 1 Brent Douty Brian Wayland Michael Bower Xiangdong Liu Lynn Leffet Qian Wang Kevin J Bowman Michael J Hansbury Changnian Liu Min Wei Yanlong Li Richard Wynn Timothy C Burn Holly K Koblish Jordan S Fridman Brian Metcalf Peggy A Scherle Andrew P Combs
Affiliations

Affiliation

  • 1 Incyte Corporation, Experimental Station, Route 141 and Henry Clay Road, Wilmington, Delaware 19880, USA.
Abstract

A hydroxyamidine chemotype has been discovered as a key pharmacophore in novel inhibitors of indoleamine 2,3-dioxygenase (IDO). Optimization led to the identification of 5l, which is a potent (HeLa IC(50) = 19 nM) competitive inhibitor of IDO. Testing of 5l in mice demonstrated pharmacodynamic inhibition of IDO, as measured by decreased kynurenine levels (>50%) in plasma and dose dependent efficacy in mice bearing GM-CSF-secreting B16 melanoma tumors.

Figures
Products